Contraception
Volume 74, Issue 6 , Pages 439-445, December 2006

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results☆

Data contained in this report were presented at the annual meeting of the American Society for Reproductive Medicine, Montreal, Canada, October 2005.

  • David F. Archer

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 757 446 7444; fax: +1 757 446 8998.
    • ,
  • Jeffrey T. Jensen

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA
    • ,
  • Julia V. Johnson

      Affiliations

    • Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington, VT 05405, USA
    • ,
  • Hannah Borisute

      Affiliations

    • Women's Health, Clinical Research/ Development, Wyeth Research, Collegeville, PA 19426, USA
    • ,
  • Gary S. Grubb

      Affiliations

    • Women's Health, Clinical Research/ Development, Wyeth Research, Collegeville, PA 19426, USA
    • ,
  • Ginger D. Constantine

      Affiliations

    • Women's Health, Clinical Research/ Development, Wyeth Research, Collegeville, PA 19426, USA

Received 30 March 2006; received in revised form 12 July 2006; accepted 12 July 2006. published online 20 September 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This study (ClinicalTrials.gov; NCT00245921) was supported by a grant from Wyeth Research (Collegeville, PA). Drs. David F. Archer, Jeffrey T. Jensen and Julia V. Johnson were investigators for this study and received research funding from Wyeth Research. Other sources of research funding and/or financial relationships include the following: Agile Therapeutics, Berlex, Genentech, Warner Chilcott, Lilly, Novo Nordisk, Ortho-McNeil, Organon International, Solvay Pharmaceuticals, Barr Laboratories, Duramed Pharmaceuticals, Johnson & Johnson and Wyeth for Dr. Archer; Berlex, Warner Chilcott, Pfizer, Organon International and Barr Laboratories for Dr. Jensen; and Berlex, Novo Nordisk, Pharmacia, Procter & Gamble for Dr. Johnson. Drs. Hannah Borisute, Gary S. Grubb and Ginger D. Constantine are employees of Wyeth Research. Other financial affiliations are Merck, Teva and Johnson & Johnson for Dr. Borisute; and Johnson & Johnson for Dr. Grubb. Dr. Constantine has no financial affiliations.

PII: S0010-7824(06)00310-6

doi:10.1016/j.contraception.2006.07.005

Contraception
Volume 74, Issue 6 , Pages 439-445, December 2006

Article Tools

* Image Usage & Resolution